The company focuses on clinical-stage immuno-oncology treatments and could see big gains going forward, according to JPMorgan. Originally published at CNBC
Find More
Trending News
- For $200, George Santos will gossip with you on Cameo
- 35 Travel Products To Get *Now* If You Have Trips Planned In 2024
- Cruise faces fines in California for withholding key details in robotaxi accident
- White House Warns Ukraine Aid Is Running Out, Pressing Congress for More
- Kodiak’s military prototype AV is a Ford F-150 pickup
- UK age assurance guidance for porn sites gives thumbs up to AI age checks, digital ID wallets and more
- Bitcoin Rally to $42K Fueled by ‘Panic Buying,’ Pushes Crypto Market Cap Over $1.5T
- BlackRock’s Rick Rieder sees first rate cut in mid-2024, thinks market is pricing in easing too soon
- Alaska-Hawaiian merger faces a Justice Department that has been skeptical of airline deals
- Evan Gershkovich Is Still Awaiting Trial in Russia, 250 Days Later